Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction

NCT03434106 | Unknown

• 1 other identifier: 2018A-005
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators hypothesize that the dry eye caused by SS may include the evaporative type, resulting from the MGD. Furthermore, the investigators hypothesize that both pSS and sSS are associated with MGD.To test our hypothesis, we conducted a prospective clinical study in patients with SS (both pSS and sSS) and MGD, and the normal population All subjects were matched for both age and gender and assessed for tear function and ocular surface signs and symptoms.

Conditions

Meibomian Gland Dysfunction; Sjögren's Syndrome

Keywords

meibomian gland dysfunction; Sjögren's syndrome; dry eye disease

Outcome Measures

Primary Outcomes (5)

• Ocular Surface Disease Index

  The OSDI questionnaire is used to quantify the dry eye symptoms. Subjects will be asked questions regarding the dry eye symptoms that they had experienced; the OSDI questions is drawn from 3 different subscales: ocular symptoms, vision-related functions, and environmental triggers. Each answer is scored on a 4-point scale from zero (indicating no problems) to four (indicating a significant problem). Responses to all of the questions are combined to generate a composite OSDI score that ranges from 0 to 100, with higher OSDI scores indicating more severe symptoms. Symptoms of dry eye, such as dryness, burning, foreign body sensation, stabbing pain, photophobia, and visual fluctuations, are also noted

  up to 3 months after tear substitutes apply

• meibomian gland function

  assessment of the quality of meibomian gland secretions, according to a published classification system (21). In brief, the grading scheme was "0" for clear excreta with small particles, "1" for opaque excreta with normal viscosity, "2" for opaque excreta with increased viscosity, and "3" for secreta that retained shape after digital expression.

  up to 3 months after tear substitutes apply

• fluorescein staining of the cornea

  Upper, lower, nasal, temporal and central quadrants were used. Superficial punctate keratopathy (SPK) in the cornea was scored from 0 to 3 in each quadrant: 0, no staining in the cornea; 1, \<5 punctuate stains; 2, \>5 punctuate stains but \<10; and 3, \>10 or filamentous staining detected. The total number was obtained by adding the scores of the four quadrants for each eye (0-15).

  up to 3 months after tear substitutes apply

• noninvasive tear breakup time

  Four IR diodes were set on the Keratograph 5 (Oculus, Wetzlar, Germany) and arranged in two pairs, located one above the other. The red ring illumination used for corneal topography was deactivated; this ensured a dark background for the examination. An illuminated ring pattern was then projected onto the cornea. At the start of the recording, the subject will be asked to blink his or her eyes three times and then to keep them open as long as possible. Irregularities in the reflected image will be observed closely. Special attention will be given to distortions and gaps in individual rings and the time such deviations from the original ring pattern took to occur. The examination will be recorded on video.

  up to 3 months after tear substitutes apply

• Schirmer's test with and without anesthesia

  The Schirmer test without anesthesia (S1T) for tear secretion function will be performed by inserting a 30-mm Schirmer tear test strip (Jingming, Tianjing, China) into the inferior fornix at the junction of the middle and lateral thirds of the lower eyelid margin. Schirmer test strips will remain in place for 5 minutes with the eyes closed. The extent of wetting will be subsequently measured according to the scale provided by the manufacturer. Potential scores ranged from 0 to 30 mm, with lower scores indicating greater tear production abnormalities.

  up to 3 months after tear substitutes apply

Secondary Outcomes (2)

• tear meniscus

  up to 3 months after tear substitutes apply

• rose bengal staining of the conjunctiva

  up to 3 months after tear substitutes apply

Study Arms (4)

primary Sjögren's syndrome

EXPERIMENTAL

The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.

Drug: liposic; Drug: Tears Naturale Forte

secondary Sjögren's syndrome

EXPERIMENTAL

The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.

Drug: liposic; Drug: Tears Naturale Forte

meibomian gland dysfunction

EXPERIMENTAL

The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.

Drug: liposic; Drug: Tears Naturale Forte

control

EXPERIMENTAL

the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.

Drug: liposic; Drug: Tears Naturale Forte

Interventions

liposic DRUG

Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen

Also known as: Carbomer

control; meibomian gland dysfunction; primary Sjögren's syndrome; secondary Sjögren's syndrome

Tears Naturale Forte DRUG

This medication is used to relieve dry, irritated eyes

Also known as: DEXTRAN/HYPROMELLOSE/GLYCERIN

control; meibomian gland dysfunction; primary Sjögren's syndrome; secondary Sjögren's syndrome

Eligibility Criteria

• Age: 45 Years - 60 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• All the subjects are female and age between 50-60 years
• Patients with primary SS fulfilled the criteria established by the European Study Group
• Patients with SLE and RA met the criteria set by the American College of Rheumatology

You may not qualify if:

• The control history of autoimmune disease

Sponsors & Collaborators

• LanZhou University: lead

Study Sites (1)

Lanzhou University Second Hospital

Lanzhou, Gansu, China

RECRUITING

MeSH Terms

Conditions

Meibomian Gland Dysfunction; Sjogren's Syndrome; Dry Eye Syndromes

Interventions

carbomer; Dextrans

Condition Hierarchy (Ancestors)

Eyelid Diseases; Eye Diseases; Arthritis, Rheumatoid; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Xerostomia; Salivary Gland Diseases; Mouth Diseases; Stomatognathic Diseases; Lacrimal Apparatus Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Glucans; Biopolymers; Polymers; Macromolecular Substances; Polysaccharides; Carbohydrates

Central Study Contacts

Jingmin Yuan, MD

CONTACT

+(86)15002626556; 15002626556@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: February 9, 2018
• First Posted: February 15, 2018
• Study Start: February 10, 2018
• Primary Completion: May 31, 2018
• Study Completion: June 30, 2018
• Last Updated: February 15, 2018

Record last verified: 2018-02

Locations

CN (1)